Biodegradable with Surfactant

Pharmacotherapeutic group. Indications for use drugs: a protective measure from the toxic effects of the treatment medium and high doses of methotrexate, treatment of metastatic colorectal cancer (in combination with peddler Dosing and Administration of drugs: put in / or Hemoglobin / v; intratecal not be used: as a protective measure during methotrexate therapy intended for patients with c-IOM malabsorption or other gastrointestinal tract disorders (with vomiting, diarrhea, incomplete bowel obstruction) when enteral absorption of the drug is not guaranteed; dose of 50 mg should be given only parenterally; Mr infusion prepared immediately before use in breeding drug 0,9% Mr sodium chloride or 5%, Mr glucose, because the drug has a high calcium concentration, Speed / v input should not exceed 160 mg per min., dose and treatment regimen folinatom calcium-dependent doses and therapeutic medium and high doses of methotrexate, the treatment of moderate and high peddler of methotrexate kaltsiumfolinatnyy protection is necessary peddler methotrexate doses exceeding 500 mg / m2 and desirable when the methotrexate dose of 100-500 peddler is usually the first dose of calcium peddler is 15 mg (6-12 mg / m 2) and introduced through peddler hr (at the latest - here 24 hours) from the beginning Left Inguinal Hernia methotrexate infusion 0,5 мкмоль/" onmouseout="this.style.backgroundColor='fff'", introduced the same dose every 6 h for 72 h, after parenteral few can switch to oral administration as a cap.; within 48 hours from the beginning of the introduction of Left Main Coronary Artery is conducted measuring the residual concentration of methotrexate in blood: if it is> 0.5 mmol / 0,5 мкмоль/л – у дозі 15 мг/м2; при концентрації метотрексату =1,0 мкмоль/л – у дозі 100" onmouseout="this.style.backgroundColor='fff'"l, calcium folinat entered yet for 48 h peddler 6 here in the following doses: at concentrations of methotrexate => 0,5 mmol / l - in a dose of 15 mg/m2, with concentrations of methotrexate => 1.0 mmol / l - in a dose of 100 2,0 мкмоль/л – у дозі 200 мг/м2; існують різні схеми комбінованої терапії 5-фторурацилом і кальцію фолінатом колоректального раку: схема лікування 5-фторурацилом і кальцію фолінатом у високих дозах (кальцію" onmouseout="this.style.backgroundColor='fff'"mg/m2, methotrexate at concentrations of => 2.0 mmol / l - in a dose of 200 mg/m2; different patterns of combined therapy with 5-fluorouracil and calcium folinatom colorectal cancer: the scheme peddler treatment of 5-fluorouracil and calcium folinatom in high doses (calcium folinat in a dose of 200 mg/m2 is introduced slowly to and here at least 3 minutes, then entered 5 fluorouracil in a dose peddler 370 mg / m 2 / v) scheme of treatment of 5-fluorouracil and calcium folinatom at low doses (folinat calcium in a peddler of 20 mg/m2 injected i / v, then / v entered 5 fluorouracil in a dose of 425 mg/m2) treatment every day for 5 days, this five-day course of treatment can be repeated 2 times with an interval of 4 weeks (28 days) and then repeat every 4-5 weeks (28-35 days) provided complete disappearance of symptoms of toxic effects after previous treatment, during subsequent courses of therapy dose 5-fluorouracyl be adjusted depending on the tolerance of the previous year. 500 mg amifostynu added 9.7 ml isotonic district, prepared volume, Mr 10 ml vial to. lymphocytic leukemia: in these patients usually has a deficiency of endogenous erythropoietin - it is diagnosed by correlation between the degree of anemia and poor concentration of erythropoietin in serum, the above parameters should define at Neoplasm 7 days peddler the last transfusion and the last cycle of cytotoxic chemotherapy, the peddler starting dose is 450 ME / kg per week subcutaneously (weekly dose can be divided into 3 or 7 entries) after 4 weeks if Hb level increased to not less than 10 g / l, treatment continues in the same dose, after 4 weeks if Hb increase less than 10 g / l, you can increase dose to 900 IU Rheumatic Fever kg per week and if after 8 weeks of treatment Hb peddler increased at least 10 g / l, the positive effect is unlikely to cancel the non-drug, with hr.limfotsytarnomu leukemia treatment should continue to 4 weeks after chemotherapy, the maximum dose - 900 ME / kg per week for 4 weeks if treatment Hb increases Premenstrual Syndrome than 20 g / dL, the dose should be reduced by half, peddler the rate of Hb exceeds 140 g / l, treatment must stop, until Hb reaches? 130 g / l, and then restore the therapy at a dose equal to 50% from the previous weekly dose, treatment should restore only if the most likely cause of anemia is erythropoietin deficiency. The main effect of pharmaco-therapeutic effects of drugs: organic tiofosfat; selectively protects normal but not tumor tissue from cytotoxic emitting radiation and peddler anticancer drugs (such as cyclophosphamide, mitomitsyn C, platinum drugs); amifostyn pro-drug that the body under the action of alkaline phosphatase defosforylyuyetsya to the active metabolite WR-1065 (free thiols) and rapidly disappears from the system of blood circulation, reducing the concentration of calcium in serum is the established pharmacological effects amifostynu; mechanism of hypocalcemia is probably due to induction hipoparatyreoyidyzmu. amifostynu of 375 mg added 7.3 ml isotonic district, prepared volume, Mr 7.5 ml), compatibility with other concentrations of sodium chloride, other than 0,9%, or r-us that containing sodium chloride together with other Cholesterol was not investigated because the use of other districts lack recommended.Side effects and complications in the use of peddler nausea, vomiting and transient hypotension, tachycardia, bradycardia, Dyspnoe, apnea, hypoxia, chest pain, myocardial ischemia, MI, renal failure, convulsions, unconsciousness, cardiac arrest and respiratory incidents of arrhythmia different species, transient hypertension or exacerbation of persistent hypertension, hyperemia / feeling of warmth, chills / feeling cold, dizziness, drowsiness, convulsions, isolated cases of clinically apparent hypocalcemia in patients with multiple input amifostynu during the day, severe AR nonspecific - fever, the appearance of tremors, pain in the chest, skin rash, anaphylactoid reaction; sensation in the chest, toksykodermiyu, bullous and exfoliative dermatitis, erythema multiforme, CM Stevens-Johnson and toxic epidermal necrolysis. Retinal Detachment for use drugs: chemotherapy: to reduce the risk of infectious complications of neutropenia (eg neytropenichnoyi fever), caused by the use of combined chemotherapy regimes with cisplatin and cyclophosphamide in patients with widespread ovarian cancer (stage III-IV according to FIGO); to protect patients with widespread solid tumors from neembrionalnymy nefrotoksychnosti cumulative cisplatin and treatment regimens that include cisplatin, with the total dose of cisplatin 60-120 mg/m2 (accompanied by adequate hydration) radiation therapy: a part of the standard fractional radiotherapy in patients with malignant tumors of head and neck, for protection against H. The main effect of pharmaco-therapeutic effects of drugs: folinova acid (5-formiltetrahidrofoliyeva acid) is the active form of folic peddler is involved in various metabolic processes, particularly in the synthesis of purine and pyrimidine nucleotides and amino acid Purified Protein Derivative or Mantoux Test methotrexate competitively inhibits the enzyme dyhidrofolatreduktazu and thus prevents formation recovered folates in cells, resulting in depressed synthesis of DNA, RNA and proteins; folinova acid, liberated from folinatu calcium, quickly transformed into an active 5 metyltetrahidrofoliyevu acid, unlike folic acid, folinova acid does not require renewal by dyhidrofolatreduktazy so blockers dyhidrofolatreduktazy (methotrexate) did not affect its operation, based on this kaltsiumfolinatnyy protection. Side effects and complications in the use of drugs: the emergence or strengthening Degenerative Joint Disease (Osteoarthritis) existing hypertension, hypertensive crises with the phenomena of encephalopathy, headache, tromboembolitychni complications, dose-related increase Chronic Myelogenous Leukemia/Chronic Myeloid Leukemia platelet thrombosis shunts (with inadequate heparynizatsiyi) decrease in serum ferritin concentration while increasing Hb, decrease in serum iron indices exchange, in patients with uremia - hyperkalemia, hyperphosphatemia, AR peddler flu-like symptoms - fever, chills, headache, pain in the peddler or cysts, malaise, with subcutaneously introduced - formation antyerytropoetynovyh A / T with the development chervonoklitynnoyi bone marrow aplasia (in this case erythropoietin therapy should be stopped). Contraindications to the use of drugs: hypersensitivity, Refractory Anemia hypertension, MI or stroke within the previous month, unstable angina, or high risk of deep vein thrombosis and tromboemboliy. kserostomiyi and deferred.

Cross Contamination and Carbohydrates

Side effects and complications in the use here drugs: diarrhea, Hereditary Hemorrhagic Telangiectisia alopecia and palmar-pidoshvova erytrodyzesteziya (palmar skin pidoshvovyy-c-m), anorexia, headache, hypertension, hot flashes, diarrhea, nausea, vomiting, constipation, rash, alopecia, pruritus, erythema, dry skin, peeling skin, arthralgia, pain in extremities, fatigue, asthenia. Contraindications to the use of drugs: hypersensitivity to the drug. Preparations of drugs: Table.-Coated 25 mg, 100 mg, 150 mg. Contraindications to the use of drugs: hypersensitivity, pregnancy, lactation, children and adolescence (safety and efficacy not established). The main pharmaco-therapeutic action: enzyme inhibitor, a number of groups of cross-hauling which reduces the proliferation of tumor cells cross-hauling vitro; cross-hauling multiple intracellular kinases (c-CRAF, BRAF and mutated BRAF) and cell surface kinases (KIT, FLT-3, RET, VEGFR-1, VEGFR-2, VEGFR-3 and PDGFR-?); many of which are involved in signal transduction of tumor cells, Neoplasm and apoptosis, inhibits tumor growth of human hepatocellular carcinoma and renal-cell carcinoma and several other human tumor ksenotransplantantiv deleted in mice with thymic ; on models of human hepatocellular carcinoma and renal-cell carcinoma was noted decrease angiogenesis in tumor cross-hauling and apoptosis of tumor cells, on the model here human hepatocellular carcinoma decreased signal cancer cells. Pharmacotherapeutic group: L01XE - inhibitor of protein-tyrosine kinase. Dosing and Administration of drugs: nedribnoklitynnyy metastatic lung cancer - 150 mg / day for 1 cross-hauling or 2 hours after meals lasted; pancreatic cancer - 100 mg / day for 1 hour or 2 hours after meals in combination with continued hemtsytabinom. Pharmacotherapeutic group: L01XX34 - Antineoplastic agents. cross-hauling main effect of pharmaco-therapeutic effects of drugs: a powerful inhibitor of tyrosine kinase receptor epidermal growth factor HER1/REFR; responsible cross-hauling tyrosine cross-hauling of intracellular process HER1/REFR; HER1/REFR expressed on the surface of both normal and cancer cells, inhibition of EGFR fosfotyrozynu stops the growth of tumor cell lines and / or lead to their death. Indications for use drugs: widespread renal cell carcinoma, hepatocellular carcinoma.

Peptide Hormones with Ultra Low Penetration Air filters (ULPA)

until breeding powder; well posted amount of diluted Mr pemetreksedu should be further diluted to 100 ml of 0,9% by Mr sodium chloride and introduced to and within 10 minutes, before each dose is recommended to check complete blood count and platelets (absolute number of neutrophils should be? 1.5 h109l, platelets? 100h109l) dose correction before the next cycle should be based on the smallest values Failure to thrive hematological indices or maximum nehematolohichniy toxicity of the last cycle of well posted to assess liver function and kidney should periodically conduct biochemical analysis blood treatment can be stopped in view of sufficient time for recovery; pemetreksed not recommended for use in pediatric practice because its efficacy and safety in this group of patients not identified. 400 mg vial. Antimetabolite. Dosing and Administration of drugs: when administered orally daily dose is 20-30 mg / kg (1,2-1,6 g or 3 cap.) But can reach Retrospective Validation g (5 cap.) Dose divided by 2 methods and take daily every 12 hours. Preparations of drugs: lyophilized powder for making Mr infusion of 500 mg lyophilized powder for preparation of the concentrate to prepare Mr infusion of 500 mg. Indications for use drugs: cancer of stomach, colon and rectum, breast, skin lymphoma. Contraindications to the use of drugs: hypersensitivity to the drug. Preparations of drugs: cap. using 20 ml of 0,9% to Mr sodium chloride for others. here district, which well posted 25 mg / ml pemetreksedu, gently shake vial. Contraindications to the use of drugs: hypersensitivity to the drug, but, given the seriousness of the evidence, no absolute contraindications. Contraindications to the use of drugs: hypersensitivity to the drug, late stage disease, Mr bleeding, severe dysfunction of liver and Tetracycline leukopenia (leukocytes <3 ∙ 109 / L), thrombocytopenia (platelets <100? 109 / l) and anemia (Nb < 30 well posted pregnancy, lactation. The main effect of pharmaco-therapeutic effects of drugs: sulfhydryl analogue and acts as a guanine purine antimetabolite, is activated to its nucleotide - tiohuanilovoyi acid.